Edition:
United States

Merus NV (MRUS.OQ)

MRUS.OQ on NASDAQ Stock Exchange Global Market

12.90USD
18 Jan 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$12.90
Open
$12.83
Day's High
$13.14
Day's Low
$12.40
Volume
33,516
Avg. Vol
10,870
52-wk High
$26.49
52-wk Low
$11.01

Latest Key Developments (Source: Significant Developments)

Merus NV Says John Crowley Resigned As Executive VP & CFO
Wednesday, 2 Jan 2019 06:33pm EST 

Jan 2 (Reuters) - Merus NV ::MERUS NV - ON JANUARY 2, 2019, JOHN J. CROWLEY RESIGNED AS THE EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER OF MERUS N.V..MERUS NV - IN CONNECTION WITH DEPARTURE, CROWLEY WILL BE ENTITLED TO RECEIVE SEVERANCE PAYMENT EQUAL TO 6 MONTHS OF HIS ANNUAL SALARY.  Full Article

Merus To Collaborate with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China
Wednesday, 2 Jan 2019 08:00am EST 

Jan 2 (Reuters) - Merus NV ::MERUS ANNOUNCES STRATEGIC COLLABORATION WITH BETTA PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE MCLA-129 IN CHINA.MERUS NV - BETTA PHARMACEUTICALS HAS AGREED TO BE RESPONSIBLE FOR CLINICAL DEVELOPMENT AND COMMERCIALIZATION OF MCLA-129 IN CHINA.MERUS - IN ADDITION TO RECEIVING UPFRONT PAYMENT, CO WILL BE ELIGIBLE TO RECEIVE PAYMENTS CONTINGENT ON BETTA ACHIEVING CERTAIN GOALS IN CHINA.MERUS NV - MERUS WILL ALSO BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES IN CHINA FROM BETTA PHARMACEUTICALS.MERUS NV - MERUS WILL RETAIN ALL RIGHTS OUTSIDE OF CHINA.MERUS NV - BETTA PHARMACEUTICALS TO FUND GLOBAL IND-ENABLING ACTIVITIES.  Full Article

Merus Announces Q2 Loss Per Share Eur 0.20
Friday, 10 Aug 2018 08:35am EDT 

Aug 10 (Reuters) - Merus NV ::MERUS ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER 2018 & MID-YEAR OPERATING RESULTS.Q2 LOSS PER SHARE EUR 0.20.Q2 REVENUE EUR 6.5 MILLION VERSUS EUR 6.2 MILLION.Q2 REVENUE VIEW EUR 4.6 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW EUR -0.62 -- THOMSON REUTERS I/B/E/S.MERUS - EXPECTS EXISTING CASH, CASH EQUIVALENTS, INVESTMENTS TO BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2020.MERUS - ENDED Q2 WITH CASH, CASH EQUIVALENTS AND INVESTMENTS OF EUR 224.1 MILLION VERSUS EUR 190.8 MILLION AT DEC 31, 2017.  Full Article

Merus Announces First Patient Dosed In Phase 1 Clinical Trial Of Mcla-158 In Patients With Solid Tumors
Thursday, 24 May 2018 07:00am EDT 

May 24 (Reuters) - Merus NV ::MERUS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF MCLA-158 IN PATIENTS WITH SOLID TUMORS.MERUS NV - MERUS PLANS TO OPEN ADDITIONAL SITES FOR MCLA-158 TRIAL IN UNITED STATES.MERUS NV - IND ACCEPTED IN APRIL BY U.S. FDA FOR MCLA-158.  Full Article

Merus Q4 Loss Per Share EUR 0.73
Thursday, 26 Apr 2018 07:00am EDT 

April 26 (Reuters) - Merus NV ::MERUS ANNOUNCES RECENT CORPORATE DEVELOPMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017.Q4 LOSS PER SHARE EUR 0.73.Q4 EARNINGS PER SHARE VIEW EUR -0.62 -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUE WAS EUR 3.8 MILLION VERSUS NEGATIVE EUR 0.4 MILLION.EXPECTS THAT ITS CURRENT CASH, CASH EQUIVALENTS AND INVESTMENTS WILL BE SUFFICIENT TO FUND ITS OPERATIONS THROUGH END OF 2020.  Full Article

Merus And Vall d'Hebron Institute Of Oncology Announce Research Collaboration
Tuesday, 20 Mar 2018 07:00am EDT 

March 20 (Reuters) - Merus Nv ::MERUS AND VALL D'HEBRON INSTITUTE OF ONCOLOGY ANNOUNCE RESEARCH COLLABORATION TO DEVELOP INNOVATIVE BISPECIFIC ANTIBODIES FOR THERAPEUTIC APPLICATIONS IN TREATMENT OF CANCER.  Full Article

Merus Says Ono Pharma Exercised Option For New Research And License Agreement
Wednesday, 14 Mar 2018 07:00am EDT 

March 14 (Reuters) - Merus Nv ::MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES.MERUS NV - ‍ONO HAS AGREED TO FUND RESEARCH ACTIVITIES AT MERUS THAT WILL GENERATE CANDIDATE BICLONICS FOR NEW PROGRAM​.MERUS NV - ‍MERUS GRANTED ONO WORLDWIDE EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE RESULTING PRODUCTS DEVELOPED THROUGH COLLABORATION​.  Full Article

Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Simcere Pharmaceutical Group ::MERUS AND SIMCERE ANNOUNCE STRATEGIC COLLABORATION ON MULTIPLE BISPECIFIC ANTIBODIES.MERUS - AGREED TO GRANT SIMCERE EXCLUSIVE LICENSE TO DEVELOP & COMMERCIALIZE IN CHINA 3 BISPECIFIC ANTIBODIES USING CO'S BICLONICS TECHNOLOGY PLATFORM.MERUS NV- CO TO BE ELIGIBLE TO GET UPFRONT & MILESTONE PAYMENTS CONTINGENT UPON SIMCERE ACHIEVING CERTAIN SPECIFIED DEVELOPMENT & COMMERCIAL GOALS.MERUS NV - MERUS WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OF ANY PRODUCTS RESULTING FROM COLLABORATION IN CHINA FROM SIMCERE.MERUS NV - SIMCERE WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OUTSIDE OF CHINA FROM MERUS.MERUS NV - ADDITIONAL FINANCIAL DETAILS WERE NOT DISCLOSED UNDER COLLABORATION WITH SIMCERE.  Full Article

Merus Nv Q3 Loss Per Share Eur 0.81
Thursday, 30 Nov 2017 07:00am EST 

Merus Nv ::MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS.Q3 LOSS PER SHARE EUR 0.81.Q3 REVENUE EUR 3.5 MILLION VERSUS EUR 1.2 MILLION.Q3 REVENUE VIEW EUR 2.2 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW EUR -0.58 -- THOMSON REUTERS I/B/E/S.- ‍EXPECTS CURRENT CASH AND CASH EQUIVALENTS BALANCE TO BE SUFFICIENT TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS WELL INTO 2019​.  Full Article

Merus announces Q2 loss per share EUR 1.12
Tuesday, 19 Sep 2017 04:05pm EDT 

Sept 19 (Reuters) - Merus NV :Merus announces second quarter 2017 financial results and highlights recent progress.Q2 loss per share EUR 1.12.Q2 revenue EUR 4.0 million versus EUR 1.1 million.Q2 revenue view eur 2.2 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view EUR -0.52 -- Thomson Reuters I/B/E/S.Merus NV - Expects that current cash and cash equivalents balance will be sufficient to fund research and development programs, operations well into 2019.  Full Article